---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-310286"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2021-10-28T23:59:59+00:00"
generated_at: "2026-06-28T16:31:45.660548+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inovio's COVID-19 vaccine INO-4800 selected for WHO Solidarity Trial Vaccines Phase 3

## Summary
- WHO confirmed Oct 26, 2021 that INO-4800 is one of two vaccines in large international Phase 3 Solidarity Trial.
- Selected by independent advisory group from ~20 candidate vaccines; two more vaccines may enter later.
- Trial recruiting volunteers at over 40 sites across Colombia, Mali, and the Philippines.
- Inovio also conducting separate global Phase 3 INNOVATE trial with partner Advaccine.

## SEC filing metadata
- accession: 0001193125-21-310286
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2021-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312521310286/0001193125-21-310286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312521310286/d235597d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-310286
- JSON: https://secwatch.observer/filing/0001193125-21-310286.json
- Plain text: https://secwatch.observer/filing/0001193125-21-310286.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.